Country selection
To offer the best possible experience tailored to your national regulatory requirements and the available product portfolio, please choose your country from the following list. This option will be saved throughout the browser session. Thank you!
User experience & privacy
We use cookies to offer you an optimal website experience. This includes cookies necessary for the operation of the website and for the control of our commercial corporate goals, as well as those only used for anonymous statistical purposes, comfort settings or to display personalized content. Please note that based on your settings, not all functions of the website may be available. To find out more, please refer to our Data Privacy Statement.

Eckert & Ziegler to Financially Back Clinical Development of Innovative Lymphoma Treatment


Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) will financially support the clinical development of two proprietary new radiopharmaceuticals for the diagnosis and treatment of malignant lymphomas. The Board of Directors today approved a first payment of 3 mm EUR in the context of an option agreement, which may lead, in the coming years and against milestones, to further payments of EUR 2 to 3 million annually. The money will support the production of pharmaceutical grade material for phase-1 trials which have already been prepared by two investigator-lead academic consortia in France and Germany targeting several forms of myeloma and lymphatic leukemia. In addition, the funds will be used for the clinical development of a complementary diagnostic labeled with the radioisotope Gallium-68.

“Stepping up outlays for clinical development does not mean that Eckert & Ziegler is abandoning its self-financing, profit-oriented business model”, explained Dr. Andreas Eckert, Chairman of the Executive Board. “Rather, we are leveraging our expertise in pharmaceutical radioisotopes in order to expand the market potential for our products, and to exploit interesting profit opportunities. In the past, we have already invested in a similar manner in companies such as OCTREOPHARM SCIENCES, CURASIGHT, IRT-SYSTEMS and MYELO THERAPEUTICS, and on average achieved a solid return on investment”.

Since the expenses will be booked as a financial investment and accounted for “at equity”, only the respective profit or loss transfers will appear in future balance sheets, but not the corresponding increase in development expenses.

About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with more 800 employees, is one of the world’s largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138,


Get in touch

Contact us regarding your questions and we will get back to you as soon as possible.
By clicking send, you give your consent for processing your personal data in accordance with our Data Privacy Statement.
Permission required
In order to submit your request it is required to load a 3rd-party service (Google Re-Captcha spam protection system). You current privacy settings prevent this from happening automatically. By clicking the button below you explicitly allow to temporarily (on this page) load 3rd party services.